Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure

Sponsor
Boehringer Ingelheim
Study ID
NCT05236673
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JARDIANCE® — DRUG
    JARDIANCE® film-coated tablets 10mg

Study Details

The primary objective of this study is to monitor the safety profile of Jardiance® in Korean patient with chronic heart failure (New York Heart Association (NYHA) class II-IV) in a routine clinical setting.

Key Dates

First listed
Feb 11, 2022
Start date
Jul 28, 2022
Status verified
Jun 2026
Primary completion
Apr 30, 2025
Completion
Apr 30, 2025

Study Design

Enrollment
676 participants (actual)

Arms

  • Arm: JARDIANCE® treated patients
    Patients in Korea with chronic heart failure who were prescribed JARDIANCE® (Empagliflozin) tablets and who were never treated with Empagliflozin before enrolment (including treatment for type 2 diabetes mellitus).

Primary Outcome Measure

Number of Patients With Adverse Events (AEs) [ Time Frame: Up to 407 days. ]

Related coverage on Hipa.ai

Find similar trials

Nationwide
Heart failure trialsCardiology trialsHeart disease trials

Related Studies